MediPharm Labs Corp.. Bolsters Operational & Leadership Expertise to Further Accelerate Development

Bolsters Leadership & Operational Expertise to Further Accelerate Growth

MediPharm Labs Corp. (“MediPharm Labs” or the “Company”-RRB- (TSXV: LABS) continues to build momentum towards its objective of becoming a global leader in pharmaceutical-grade cannabis concentrates, by adding to its current management strength. MediPharm Labs is very happy to welcome industry veteran David Mayers as rsquo & the Company;s recently appointed Chief Operating Officer, and leading cannabis compliance professional Anuja Siwakoti as the organization ’s recently appointed Director of Global Regulatory and Scientific Affairs. Both of these senior staff members will play critical roles in leading rsquo MediPharm Labs & ; assertive expansion programs in Canada and into international markets, where cannabis is legal.

&David; ldquo and Anuja reflect the high degree of expertise and professionalism says Pat McCutcheon, CEO and President of MediPharm Labs. “Our vision of international leadership in cannabis isolates and concentrates requires this standard of qualifications. We keep building strength and our targets to meet. ”

David Mayers brings over 28 years of pharmaceutical direction in large multinational firms and small privately held organizations, with extensive experience in corporate strategy and oversight, research and development (“R&D”-RRB-, quality, lean sigma, production, supply chain, procurement, information technology, finance, product development, product launch, facility expansion, security and the management of controlled substances. Starting his career as a chemist for SmithKline Beecham (now GlaxoSmithKline), David progressed through roles of increasing responsibility for Taro Pharmaceutical Industries Ltd., Merck KGaA, Apotex Inc. and afterwards Purdue Pharma (Canada). Most recently, David served as the Chief Operating Officer and member of the Board of Directors for Impopharma Inc., a pharmaceutical company specializing in the development and launching of pulmonary and nasal inhalation pharmaceutical products. In his role in Impopharma Inc., David led a turn-around of the business ’s R&D applications and eased its acquisition. David received his Hons. B.Sc. in Biological Science from the University of Guelph and an MBA from the Rotman School of Business, University of Toronto. 

Anuja Siwakoti has 8 years of experience in cannabis work, academia and research . Most recently, Anuja worked as a Senior Quality/Regulatory Consultant at Cannabis Compliance Inc., global cannabis consulting firm. In that role, she provided regulatory and quality consulting services to over 50 clients, assisting with operational gap assessment and GPP/GMP audits, directing close to one dozen clients with licence reception from Health Canada, and navigating through the cannabis regulatory authority of numerous countries/US states. Anuja previously worked for two and a half years in Aphria Inc., one of Canada’s leading LPs, in a senior role in the Quality Department. She has spoken at numerous conferences and been printed in journals. Anuja holds a Masters degree.

Operational Expertise

MediPharm Labs has established a team with industry leading expertise in the creation of pharmaceutical-grade cannabis concentrates. Under the direction of our recently appointed Chief Operating Officer, David Mayers, and with the advice and discipline of our Director of Quality Control and Assurance, Dr. Chris Talpas, MediPharm has developed proprietary methodologies and operational efficiencies which have been leveraged to build a library of purified concentrates and distillates.

The organization ’s production has been achieved through the operation of two production shifts daily. Operations are directed by sector specialists with profound expertise in cannabis extraction, complemented by 10 years of pharmaceutical manufacturing experience to GMP standards. Adjunct cannabis consultants provide additional knowledge from their home markets of California (legal adult-use since Jan 2018 with 150 allowable products) and from the uk with 20+ years chromatophary expertise.

A first-mover in cannabis purification and extraction MediPharm Labs, in Canada has invested in proprietary methodologies , customized state-of-the-art technology, a specialist group and facilities to deliver pharmaceutical-grade and exactly dosable cannabis oils and cannabis concentrates for derivative products that were advanced. In which globally cannabis centers have emerged as a preferred basis for consumption and are the critical components for isolate and infused products for the adult and medical use markets. MediPharm Labs is in discussions regarding the importing and exporting of cannabis where. Anuja Siwakoti, as the Director of Global Regulatory and Scientific Affairs will assist in advancing MediPharm’s global expansion.

Around MediPharm Labs Corp..

MediPharm Labs, through its subsidiary, is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a certified manufacturer for cannabis oil production below the accessibility to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil using a competitive edge. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and isolation and purification. MediPharm Labs, through its subsidiary, provides contract processing of cannabis to Canadian licensed manufacturers and appropriate international growers, providing integrity-assured cannabis oil to qualified companies for sale. Additionally, MediPharm Labs provides formulations, raw materials, processing and packaging for the creation of ready-to-sell advanced derivative products. Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application procedure with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

Further Information

For further information, please see the Company’s website at www.medipharmlabs.com or contact:

Pat McCutcheon, CEO and President of MediPharm Labs
Telephone:             705-719-7425 ext. 216
Email:              investors@medipharmlabs.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) takes responsibility for the adequacy or accuracy of this release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” and “forward-looking statements” (jointly, “forward-looking statements”-RRB- within the meaning of the applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any announcement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not necessarily using phrases such as “anticipates ”, or “does not anticipate ”, “is expected”, “expects ” or “does not anticipate”, “aims ”, “funding ”, “scheduled”, “forecasts”, “quotes ”, “considers ” & “plans ” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “could ”, “could ” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, future growth and expansion goals. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors that might cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure. Accordingly, readers shouldn’t place undue reliance on the forward-looking statements and information. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, if they change.

Released at Fri, 19 October 2018 14:46:20 +0000

Posted in: News

Comments are closed.